Syngenis Labs has received a $363,000 research and development (R&D) tax refund, according to multiple Australian outlets. The refund comes after the company recently raised about $4 million ahead of a planned initial public offering.
The money is intended to support Syngenis’ development work in Western Australia, where it is building an integrated platform combining AI capabilities with RNA and DNA-related manufacturing. The reported focus is on expanding its Australian RNA and DNA manufacturing operations.
Across the sources, the core details are consistent: the size of the R&D refund, the approximate amount of the earlier pre-IPO raise, and the stated purpose of funding platform build-out in Perth. The West Australian frames the refund as “non-dilutive” support, while the other outlets primarily report the figures and the company’s broader development plans.
Overall, the reporting aligns on the company’s recent financing and how it plans to use the R&D refund as part of its biotech expansion.
